Free Trial
NASDAQ:LRMR

Larimar Therapeutics Q1 2025 Earnings Report

Larimar Therapeutics logo
$2.97 +0.11 (+3.85%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$3.06 +0.09 (+2.86%)
As of 05/2/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Larimar Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.42
Beat/Miss
N/A
One Year Ago EPS
N/A

Larimar Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Larimar Therapeutics Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Larimar Therapeutics Earnings Headlines

What is Wedbush's Forecast for LRMR Q2 Earnings?
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
See More Larimar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email.

About Larimar Therapeutics

Larimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

View Larimar Therapeutics Profile

More Earnings Resources from MarketBeat